1
|
Imoisili OE, Chung A, Tong X, Hayes DK, Loustalot F. Prevalence of Stroke - Behavioral Risk Factor Surveillance System, United States, 2011-2022. MMWR. MORBIDITY AND MORTALITY WEEKLY REPORT 2024; 73:449-455. [PMID: 38781110 PMCID: PMC11115433 DOI: 10.15585/mmwr.mm7320a1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/25/2024]
Abstract
Stroke was the fifth leading cause of death in the United States in 2021, and cost U.S. residents approximately $56.2 billion during 2019-2020. During 2006-2010, self-reported stroke prevalence among noninstitutionalized adults had a relative decrease of 3.7%. Data from the Behavioral Risk Factor Surveillance System were used to analyze age-standardized stroke prevalence during 2011-2022 among adults aged ≥18 years. From 2011-2013 to 2020-2022, overall self-reported stroke prevalence increased by 7.8% nationwide. Increases occurred among adults aged 18-64 years; females and males; non-Hispanic Black or African American (Black), non-Hispanic White (White), and Hispanic or Latino (Hispanic) persons; and adults with less than a college degree. Stroke prevalence was higher among adults aged ≥65 years than among younger adults; among non-Hispanic American Indian or Alaska Native, non-Hispanic Native Hawaiian or Pacific Islander, and Black adults than among White adults; and among adults with less than a high school education than among those with higher levels of education. Stroke prevalence decreased in the District of Columbia and increased in 10 states. Initiatives to promote knowledge of the signs and symptoms of stroke, and the identification of disparities in stroke prevalence, might help to focus clinical and programmatic interventions, such as the Million Hearts 2027 initiative or the Paul Coverdell National Acute Stroke Program, to improve prevention and treatment of stroke.
Collapse
Affiliation(s)
- Omoye E. Imoisili
- Division for Heart Disease and Stroke Prevention, National Center for Chronic Disease Prevention and Health Promotion, CDC
| | - Alina Chung
- Division for Heart Disease and Stroke Prevention, National Center for Chronic Disease Prevention and Health Promotion, CDC
| | - Xin Tong
- Division for Heart Disease and Stroke Prevention, National Center for Chronic Disease Prevention and Health Promotion, CDC
| | - Donald K. Hayes
- Division for Heart Disease and Stroke Prevention, National Center for Chronic Disease Prevention and Health Promotion, CDC
| | - Fleetwood Loustalot
- Division for Heart Disease and Stroke Prevention, National Center for Chronic Disease Prevention and Health Promotion, CDC
| |
Collapse
|
2
|
Toska E, Mayrovitz HN. Opioid Impacts on Cardiovascular Health. Cureus 2023; 15:e46224. [PMID: 37905258 PMCID: PMC10613512 DOI: 10.7759/cureus.46224] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2023] [Accepted: 09/29/2023] [Indexed: 11/02/2023] Open
Abstract
The prevalence of opioid use in the current opioid epidemic era has led to a public health emergency due to the ties to mortality and morbidity. Studies have investigated opioids' impacts on different aspects of cardiovascular health, although there seems to be a lack of a current concise review. Therefore, the aim of this literature review is to provide a summary of the most recent studies from the past decade that postulate a connection between opioids and their impact on cardiovascular health while highlighting conflicting areas among published research. For this literature review, three databases, PubMed (NLM), EMBASE, and Web of Science (Core Collection), were searched for full peer-reviewed articles written in English about human subjects and published between 2013 and 2023 inclusive. The following initial approach was to search for terms in the title of articles: "opioid AND ("vascular" OR "artery" OR "vein" OR "heart rate" OR "infarct" OR "stroke" OR "aortic" OR "cardiovascular disease"). After assessing for duplicate articles from the three databases, the remaining articles were assessed for inclusion eligibility. In the present review, a brief description of the overall role of opioid receptors is provided followed by the literature findings. These findings indicate potentially important negative impacts of opioid use on cardiovascular health in a number of areas. These include opioid-associated increases in the following: (1) vascular aging based on demonstrated increases in arterial stiffness, (2) opioid-related reductions in heart rate variability (HRV) and its implications on morbidity and mortality, (3) opioid's impacts on coronary artery and coronary heart disease (CHD), (4) opioids as a risk factor for atrial fibrillation (AF) and (5) opioid use as a risk factor for vascular occlusion processes. In addition to these broad cardiovascular effects, other aspects of concern are related to the potential impacts of withdrawal from opioid use, which, when done rapidly, are associated with increases in blood pressure and a decrease in HRV.
Collapse
Affiliation(s)
- Erjola Toska
- Osteopathic Medicine, Nova Southeastern University Dr. Kiran C. Patel College of Osteopathic Medicine, Fort Lauderdale, USA
| | - Harvey N Mayrovitz
- Medical Education, Nova Southeastern University Dr. Kiran C. Patel College of Allopathic Medicine, Fort Lauderdale, USA
| |
Collapse
|
3
|
Barreveld AM, Mendelson A, Deiling B, Armstrong CA, Viscusi ER, Kohan LR. Caring for Our Patients With Opioid Use Disorder in the Perioperative Period: A Guide for the Anesthesiologist. Anesth Analg 2023; 137:488-507. [PMID: 37590794 DOI: 10.1213/ane.0000000000006280] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/19/2023]
Abstract
Opioid use disorder (OUD) is a rising public health crisis, impacting millions of individuals and families worldwide. Anesthesiologists can play a key role in improving morbidity and mortality around the time of surgery by informing perioperative teams and guiding evidence-based care and access to life-saving treatment for patients with active OUD or in recovery. This article serves as an educational resource for the anesthesiologist caring for patients with OUD and is the second in a series of articles published in Anesthesia & Analgesia on the anesthetic and analgesic management of patients with substance use disorders. The article is divided into 4 sections: (1) background to OUD, treatment principles, and the anesthesiologist; (2) perioperative considerations for patients prescribed medications for OUD (MOUD); (3) perioperative considerations for patients with active, untreated OUD; and (4) nonopioid and nonpharmacologic principles of multimodal perioperative pain management for patients with untreated, active OUD, or in recovery. The article concludes with a stepwise approach for the anesthesiologist to support OUD treatment and recovery. The anesthesiologist is an important leader of the perioperative team to promote these suggested best practices and help save lives.
Collapse
Affiliation(s)
- Antje M Barreveld
- From the Department of Anesthesiology, Tufts University School of Medicine, Newton-Wellesley Hospital, Newton, Massachusetts
| | - Andrew Mendelson
- Department of Anesthesiology, University of Virginia School of Medicine, University of Virginia Hospital, Charlottesville, Virginia
| | - Brittany Deiling
- Department of Anesthesiology, University of Virginia School of Medicine, University of Virginia Hospital, Charlottesville, Virginia
| | - Catharina A Armstrong
- Department of Medicine, Tufts University School of Medicine, Newton-Wellesley Hospital, Newton, Massachusetts
| | - Eugene R Viscusi
- Department of Anesthesiology, Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia, Pennsylvania
| | - Lynn R Kohan
- Department of Anesthesiology, University of Virginia School of Medicine, University of Virginia Hospital, Charlottesville, Virginia
| |
Collapse
|
4
|
Xia C, Hoffman H, Anikpezie N, Philip K, Wee C, Choudhry R, Albright KC, Masoud H, Beutler T, Schmidt E, Gould G, Patel SD, Akano EO, Morris N, Chaturvedi S, Aneni E, Lamikanra O, Chin L, Latorre JG, Otite FO. Trends in the Incidence of Spontaneous Subarachnoid Hemorrhages in the United States, 2007-2017. Neurology 2023; 100:e123-e132. [PMID: 36289004 PMCID: PMC10499430 DOI: 10.1212/wnl.0000000000201340] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2022] [Accepted: 08/17/2022] [Indexed: 02/05/2023] Open
Abstract
BACKGROUND AND OBJECTIVE To test the hypothesis that age-specific, sex-specific, and race-specific and ethnicity-specific incidence of nontraumatic subarachnoid hemorrhage (SAH) increased in the United States over the last decade. METHODS In this retrospective cohort study, validated International Classification of Diseases codes were used to identify all new cases of SAH (n = 39,475) in the State Inpatients Databases of New York and Florida (2007-2017). SAH counts were combined with Census data to calculate incidence. Joinpoint regression was used to compute the annual percentage change (APC) in incidence and to compare trends over time between demographic subgroups. RESULTS Across the study period, the average annual age-standardized/sex-standardized incidence of SAH in cases per 100,000 population was 11.4, but incidence was significantly higher in women (13.1) compared with that in men (9.6), p < 0.001. Incidence also increased with age in both sexes (men aged 20-44 years: 3.6; men aged 65 years or older: 22.0). Age-standardized and sex-standardized incidence was greater in Black patients (15.4) compared with that in non-Hispanic White (NHW) patients (9.9) and other races and ethnicities, p < 0.001. On joinpoint regression, incidence increased over time (APC 0.7%, p < 0.001), but most of this increase occurred in men aged 45-64 years (APC 1.1%, p = 0.006), men aged 65 years or older (APC 2.3%, p < 0.001), and women aged 65 years or older (APC 0.7%, p = 0.009). Incidence in women aged 20-44 years declined (APC -0.7%, p = 0.017), while those in other age/sex groups remained unchanged over time. Incidence increased in Black patients (APC 1.8%, p = 0.014), whereas that in Asian, Hispanic, and NHW patients did not change significantly over time. DISCUSSION Nontraumatic SAH incidence in the United States increased over the last decade predominantly in middle-aged men and elderly men and women. Incidence is disproportionately higher and increasing in Black patients, whereas that in other races and ethnicities did not change significantly over time.
Collapse
Affiliation(s)
- Christina Xia
- From the Departments of Neurology (C.X., K.P., C.W., R.C., K.C.A., H.M., E.S., J.G.L., F.O.O.M.), and Neurosurgery (H.H., T.B., G.G., L.C.), SUNY Upstate Medical University, Syracuse, NY; Department of Population Health Science (N.A.), University of Mississippi Medical Center, Jackson; Department of Neurology (S.D.P.), University of California Los Angeles; Molecular Neuropharmacology Unit (E.O.A.), National Institute of Neurological Disorders and Stroke, Bethesda, MD; Department of Neurology (N.M., S.C.), University of Maryland, Baltimore; Department of Cardiology (E.A.), Yale University, New Haven, CT; andDepartment of Critical Care (O.L.), Springfield Clinic, IL
| | - Haydn Hoffman
- From the Departments of Neurology (C.X., K.P., C.W., R.C., K.C.A., H.M., E.S., J.G.L., F.O.O.M.), and Neurosurgery (H.H., T.B., G.G., L.C.), SUNY Upstate Medical University, Syracuse, NY; Department of Population Health Science (N.A.), University of Mississippi Medical Center, Jackson; Department of Neurology (S.D.P.), University of California Los Angeles; Molecular Neuropharmacology Unit (E.O.A.), National Institute of Neurological Disorders and Stroke, Bethesda, MD; Department of Neurology (N.M., S.C.), University of Maryland, Baltimore; Department of Cardiology (E.A.), Yale University, New Haven, CT; andDepartment of Critical Care (O.L.), Springfield Clinic, IL
| | - Nnabuchi Anikpezie
- From the Departments of Neurology (C.X., K.P., C.W., R.C., K.C.A., H.M., E.S., J.G.L., F.O.O.M.), and Neurosurgery (H.H., T.B., G.G., L.C.), SUNY Upstate Medical University, Syracuse, NY; Department of Population Health Science (N.A.), University of Mississippi Medical Center, Jackson; Department of Neurology (S.D.P.), University of California Los Angeles; Molecular Neuropharmacology Unit (E.O.A.), National Institute of Neurological Disorders and Stroke, Bethesda, MD; Department of Neurology (N.M., S.C.), University of Maryland, Baltimore; Department of Cardiology (E.A.), Yale University, New Haven, CT; andDepartment of Critical Care (O.L.), Springfield Clinic, IL
| | - Karan Philip
- From the Departments of Neurology (C.X., K.P., C.W., R.C., K.C.A., H.M., E.S., J.G.L., F.O.O.M.), and Neurosurgery (H.H., T.B., G.G., L.C.), SUNY Upstate Medical University, Syracuse, NY; Department of Population Health Science (N.A.), University of Mississippi Medical Center, Jackson; Department of Neurology (S.D.P.), University of California Los Angeles; Molecular Neuropharmacology Unit (E.O.A.), National Institute of Neurological Disorders and Stroke, Bethesda, MD; Department of Neurology (N.M., S.C.), University of Maryland, Baltimore; Department of Cardiology (E.A.), Yale University, New Haven, CT; andDepartment of Critical Care (O.L.), Springfield Clinic, IL
| | - Claribel Wee
- From the Departments of Neurology (C.X., K.P., C.W., R.C., K.C.A., H.M., E.S., J.G.L., F.O.O.M.), and Neurosurgery (H.H., T.B., G.G., L.C.), SUNY Upstate Medical University, Syracuse, NY; Department of Population Health Science (N.A.), University of Mississippi Medical Center, Jackson; Department of Neurology (S.D.P.), University of California Los Angeles; Molecular Neuropharmacology Unit (E.O.A.), National Institute of Neurological Disorders and Stroke, Bethesda, MD; Department of Neurology (N.M., S.C.), University of Maryland, Baltimore; Department of Cardiology (E.A.), Yale University, New Haven, CT; andDepartment of Critical Care (O.L.), Springfield Clinic, IL
| | - Reema Choudhry
- From the Departments of Neurology (C.X., K.P., C.W., R.C., K.C.A., H.M., E.S., J.G.L., F.O.O.M.), and Neurosurgery (H.H., T.B., G.G., L.C.), SUNY Upstate Medical University, Syracuse, NY; Department of Population Health Science (N.A.), University of Mississippi Medical Center, Jackson; Department of Neurology (S.D.P.), University of California Los Angeles; Molecular Neuropharmacology Unit (E.O.A.), National Institute of Neurological Disorders and Stroke, Bethesda, MD; Department of Neurology (N.M., S.C.), University of Maryland, Baltimore; Department of Cardiology (E.A.), Yale University, New Haven, CT; andDepartment of Critical Care (O.L.), Springfield Clinic, IL
| | - Karen C Albright
- From the Departments of Neurology (C.X., K.P., C.W., R.C., K.C.A., H.M., E.S., J.G.L., F.O.O.M.), and Neurosurgery (H.H., T.B., G.G., L.C.), SUNY Upstate Medical University, Syracuse, NY; Department of Population Health Science (N.A.), University of Mississippi Medical Center, Jackson; Department of Neurology (S.D.P.), University of California Los Angeles; Molecular Neuropharmacology Unit (E.O.A.), National Institute of Neurological Disorders and Stroke, Bethesda, MD; Department of Neurology (N.M., S.C.), University of Maryland, Baltimore; Department of Cardiology (E.A.), Yale University, New Haven, CT; andDepartment of Critical Care (O.L.), Springfield Clinic, IL
| | - Hesham Masoud
- From the Departments of Neurology (C.X., K.P., C.W., R.C., K.C.A., H.M., E.S., J.G.L., F.O.O.M.), and Neurosurgery (H.H., T.B., G.G., L.C.), SUNY Upstate Medical University, Syracuse, NY; Department of Population Health Science (N.A.), University of Mississippi Medical Center, Jackson; Department of Neurology (S.D.P.), University of California Los Angeles; Molecular Neuropharmacology Unit (E.O.A.), National Institute of Neurological Disorders and Stroke, Bethesda, MD; Department of Neurology (N.M., S.C.), University of Maryland, Baltimore; Department of Cardiology (E.A.), Yale University, New Haven, CT; andDepartment of Critical Care (O.L.), Springfield Clinic, IL
| | - Timothy Beutler
- From the Departments of Neurology (C.X., K.P., C.W., R.C., K.C.A., H.M., E.S., J.G.L., F.O.O.M.), and Neurosurgery (H.H., T.B., G.G., L.C.), SUNY Upstate Medical University, Syracuse, NY; Department of Population Health Science (N.A.), University of Mississippi Medical Center, Jackson; Department of Neurology (S.D.P.), University of California Los Angeles; Molecular Neuropharmacology Unit (E.O.A.), National Institute of Neurological Disorders and Stroke, Bethesda, MD; Department of Neurology (N.M., S.C.), University of Maryland, Baltimore; Department of Cardiology (E.A.), Yale University, New Haven, CT; andDepartment of Critical Care (O.L.), Springfield Clinic, IL
| | - Elena Schmidt
- From the Departments of Neurology (C.X., K.P., C.W., R.C., K.C.A., H.M., E.S., J.G.L., F.O.O.M.), and Neurosurgery (H.H., T.B., G.G., L.C.), SUNY Upstate Medical University, Syracuse, NY; Department of Population Health Science (N.A.), University of Mississippi Medical Center, Jackson; Department of Neurology (S.D.P.), University of California Los Angeles; Molecular Neuropharmacology Unit (E.O.A.), National Institute of Neurological Disorders and Stroke, Bethesda, MD; Department of Neurology (N.M., S.C.), University of Maryland, Baltimore; Department of Cardiology (E.A.), Yale University, New Haven, CT; andDepartment of Critical Care (O.L.), Springfield Clinic, IL
| | - Grahame Gould
- From the Departments of Neurology (C.X., K.P., C.W., R.C., K.C.A., H.M., E.S., J.G.L., F.O.O.M.), and Neurosurgery (H.H., T.B., G.G., L.C.), SUNY Upstate Medical University, Syracuse, NY; Department of Population Health Science (N.A.), University of Mississippi Medical Center, Jackson; Department of Neurology (S.D.P.), University of California Los Angeles; Molecular Neuropharmacology Unit (E.O.A.), National Institute of Neurological Disorders and Stroke, Bethesda, MD; Department of Neurology (N.M., S.C.), University of Maryland, Baltimore; Department of Cardiology (E.A.), Yale University, New Haven, CT; andDepartment of Critical Care (O.L.), Springfield Clinic, IL
| | - Smit D Patel
- From the Departments of Neurology (C.X., K.P., C.W., R.C., K.C.A., H.M., E.S., J.G.L., F.O.O.M.), and Neurosurgery (H.H., T.B., G.G., L.C.), SUNY Upstate Medical University, Syracuse, NY; Department of Population Health Science (N.A.), University of Mississippi Medical Center, Jackson; Department of Neurology (S.D.P.), University of California Los Angeles; Molecular Neuropharmacology Unit (E.O.A.), National Institute of Neurological Disorders and Stroke, Bethesda, MD; Department of Neurology (N.M., S.C.), University of Maryland, Baltimore; Department of Cardiology (E.A.), Yale University, New Haven, CT; andDepartment of Critical Care (O.L.), Springfield Clinic, IL
| | - Emmanuel Oladele Akano
- From the Departments of Neurology (C.X., K.P., C.W., R.C., K.C.A., H.M., E.S., J.G.L., F.O.O.M.), and Neurosurgery (H.H., T.B., G.G., L.C.), SUNY Upstate Medical University, Syracuse, NY; Department of Population Health Science (N.A.), University of Mississippi Medical Center, Jackson; Department of Neurology (S.D.P.), University of California Los Angeles; Molecular Neuropharmacology Unit (E.O.A.), National Institute of Neurological Disorders and Stroke, Bethesda, MD; Department of Neurology (N.M., S.C.), University of Maryland, Baltimore; Department of Cardiology (E.A.), Yale University, New Haven, CT; andDepartment of Critical Care (O.L.), Springfield Clinic, IL
| | - Nicholas Morris
- From the Departments of Neurology (C.X., K.P., C.W., R.C., K.C.A., H.M., E.S., J.G.L., F.O.O.M.), and Neurosurgery (H.H., T.B., G.G., L.C.), SUNY Upstate Medical University, Syracuse, NY; Department of Population Health Science (N.A.), University of Mississippi Medical Center, Jackson; Department of Neurology (S.D.P.), University of California Los Angeles; Molecular Neuropharmacology Unit (E.O.A.), National Institute of Neurological Disorders and Stroke, Bethesda, MD; Department of Neurology (N.M., S.C.), University of Maryland, Baltimore; Department of Cardiology (E.A.), Yale University, New Haven, CT; andDepartment of Critical Care (O.L.), Springfield Clinic, IL
| | - Seemant Chaturvedi
- From the Departments of Neurology (C.X., K.P., C.W., R.C., K.C.A., H.M., E.S., J.G.L., F.O.O.M.), and Neurosurgery (H.H., T.B., G.G., L.C.), SUNY Upstate Medical University, Syracuse, NY; Department of Population Health Science (N.A.), University of Mississippi Medical Center, Jackson; Department of Neurology (S.D.P.), University of California Los Angeles; Molecular Neuropharmacology Unit (E.O.A.), National Institute of Neurological Disorders and Stroke, Bethesda, MD; Department of Neurology (N.M., S.C.), University of Maryland, Baltimore; Department of Cardiology (E.A.), Yale University, New Haven, CT; andDepartment of Critical Care (O.L.), Springfield Clinic, IL
| | - Ehimen Aneni
- From the Departments of Neurology (C.X., K.P., C.W., R.C., K.C.A., H.M., E.S., J.G.L., F.O.O.M.), and Neurosurgery (H.H., T.B., G.G., L.C.), SUNY Upstate Medical University, Syracuse, NY; Department of Population Health Science (N.A.), University of Mississippi Medical Center, Jackson; Department of Neurology (S.D.P.), University of California Los Angeles; Molecular Neuropharmacology Unit (E.O.A.), National Institute of Neurological Disorders and Stroke, Bethesda, MD; Department of Neurology (N.M., S.C.), University of Maryland, Baltimore; Department of Cardiology (E.A.), Yale University, New Haven, CT; andDepartment of Critical Care (O.L.), Springfield Clinic, IL
| | - Oluwatomi Lamikanra
- From the Departments of Neurology (C.X., K.P., C.W., R.C., K.C.A., H.M., E.S., J.G.L., F.O.O.M.), and Neurosurgery (H.H., T.B., G.G., L.C.), SUNY Upstate Medical University, Syracuse, NY; Department of Population Health Science (N.A.), University of Mississippi Medical Center, Jackson; Department of Neurology (S.D.P.), University of California Los Angeles; Molecular Neuropharmacology Unit (E.O.A.), National Institute of Neurological Disorders and Stroke, Bethesda, MD; Department of Neurology (N.M., S.C.), University of Maryland, Baltimore; Department of Cardiology (E.A.), Yale University, New Haven, CT; andDepartment of Critical Care (O.L.), Springfield Clinic, IL
| | - Lawrence Chin
- From the Departments of Neurology (C.X., K.P., C.W., R.C., K.C.A., H.M., E.S., J.G.L., F.O.O.M.), and Neurosurgery (H.H., T.B., G.G., L.C.), SUNY Upstate Medical University, Syracuse, NY; Department of Population Health Science (N.A.), University of Mississippi Medical Center, Jackson; Department of Neurology (S.D.P.), University of California Los Angeles; Molecular Neuropharmacology Unit (E.O.A.), National Institute of Neurological Disorders and Stroke, Bethesda, MD; Department of Neurology (N.M., S.C.), University of Maryland, Baltimore; Department of Cardiology (E.A.), Yale University, New Haven, CT; andDepartment of Critical Care (O.L.), Springfield Clinic, IL
| | - Julius G Latorre
- From the Departments of Neurology (C.X., K.P., C.W., R.C., K.C.A., H.M., E.S., J.G.L., F.O.O.M.), and Neurosurgery (H.H., T.B., G.G., L.C.), SUNY Upstate Medical University, Syracuse, NY; Department of Population Health Science (N.A.), University of Mississippi Medical Center, Jackson; Department of Neurology (S.D.P.), University of California Los Angeles; Molecular Neuropharmacology Unit (E.O.A.), National Institute of Neurological Disorders and Stroke, Bethesda, MD; Department of Neurology (N.M., S.C.), University of Maryland, Baltimore; Department of Cardiology (E.A.), Yale University, New Haven, CT; andDepartment of Critical Care (O.L.), Springfield Clinic, IL
| | - Fadar Oliver Otite
- From the Departments of Neurology (C.X., K.P., C.W., R.C., K.C.A., H.M., E.S., J.G.L., F.O.O.M.), and Neurosurgery (H.H., T.B., G.G., L.C.), SUNY Upstate Medical University, Syracuse, NY; Department of Population Health Science (N.A.), University of Mississippi Medical Center, Jackson; Department of Neurology (S.D.P.), University of California Los Angeles; Molecular Neuropharmacology Unit (E.O.A.), National Institute of Neurological Disorders and Stroke, Bethesda, MD; Department of Neurology (N.M., S.C.), University of Maryland, Baltimore; Department of Cardiology (E.A.), Yale University, New Haven, CT; andDepartment of Critical Care (O.L.), Springfield Clinic, IL.
| |
Collapse
|
5
|
Jolobe OMP. The workup of prospective candidates for thrombolytic therapy of stroke. Am J Emerg Med 2023; 63:172-174. [PMID: 36319482 DOI: 10.1016/j.ajem.2022.10.037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2022] [Accepted: 10/22/2022] [Indexed: 11/06/2022] Open
Affiliation(s)
- Oscar M P Jolobe
- British Medical Association, BMA House, Tavistock Square, London WC1 9JP, United Kingdom.
| |
Collapse
|
6
|
Badar F, Ashraf A, Bhuiyan MR, Bimal T, Iftikhar A. A Peculiar Case of Fentanyl-Induced Cardiomyopathy. Cureus 2022; 14:e27708. [PMID: 36081981 PMCID: PMC9440989 DOI: 10.7759/cureus.27708] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/05/2022] [Indexed: 11/05/2022] Open
Abstract
An alarming rise in prescription and non-prescription misuse of opioids has been observed recently, leading to potentially devastating consequences. Opioid misuse contributes to cardiac risk burden and can cause diseases such as acute coronary syndrome, congestive heart failure, arrhythmias, QTc prolongation, and endocarditis. Here, we describe the case of a 35-year-old male with recreational fentanyl use who was found to have a cardiogenic shock on point-of-care ultrasound (POCUS), likely due to fentanyl-induced cardiomyopathy. Opioid-induced cardiomyopathy without any underlying cardiac disease in an adult appears to be a rare case. Our case highlights the importance of promptly recognizing fentanyl toxicity, screening for possible cardiomyopathy secondary to its use, and emergent resuscitation with the maintenance of ventilation, diuretics, and vasopressor support. The use of the reversal agent, naloxone, is a crucial part of management.
Collapse
|
7
|
Nelson KR, Dolbec K, Watson W, Yuan H, Ibraheem M. Review of Neurologic Comorbidities in Hospitalized Patients With Opioid Abuse. Neurol Clin Pract 2022; 11:527-533. [PMID: 34992960 DOI: 10.1212/cpj.0000000000001080] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2020] [Accepted: 02/26/2021] [Indexed: 11/15/2022]
Abstract
Purpose of Review To determine the prevalence and burden of neurologic comorbidities in hospitalized patients with opioid abuse. Recent Findings From 1 year of hospital discharges, 2,182 patients with opioid abuse were identified (prevalence 6.3%), with abuse greater among younger patients (p < 0.0001), women (p < 0.0001), Whites (p < 0.0001), and urban population (p = 0.028). Matching for age, sex, race, and urban-rural residence, 347 patients were reviewed, and 179 (52%) had a neurologic comorbidity. The comorbidities frequently overlapped and included encephalopathy (130), neuromuscular disorders (42), seizures (23), spine disorders (23), strokes (20), CNS infections (3), and movement disorders (2). Abuse patients with neurologic comorbidities experienced substantially greater number of hospital and intensive care unit days and mortality, independent of overdose. Summary Neurologic comorbidities are a frequent and heretofore underappreciated contributor to the disease burden of hospitalized patients with opioid abuse. The importance of neurologic comorbidities should be included in the public health discussions surrounding the opioid epidemic.
Collapse
Affiliation(s)
- Kevin R Nelson
- Department of Neurology (KRN, KD, WW, MI), University of Kentucky, Lexington; Department of Neurology (WW), Uniformed Services University, Bethesda, MD; Performance Analytics Center of Excellence (HY), University of Kentucky Health Care, Lexington; Department of Epidemiology (MI), University of Kentucky, Lexington; and Lexington VA Health Care System (Troy Bowling Campus) (MI), US Department of Veterans Affairs, KY
| | - Katelyn Dolbec
- Department of Neurology (KRN, KD, WW, MI), University of Kentucky, Lexington; Department of Neurology (WW), Uniformed Services University, Bethesda, MD; Performance Analytics Center of Excellence (HY), University of Kentucky Health Care, Lexington; Department of Epidemiology (MI), University of Kentucky, Lexington; and Lexington VA Health Care System (Troy Bowling Campus) (MI), US Department of Veterans Affairs, KY
| | - William Watson
- Department of Neurology (KRN, KD, WW, MI), University of Kentucky, Lexington; Department of Neurology (WW), Uniformed Services University, Bethesda, MD; Performance Analytics Center of Excellence (HY), University of Kentucky Health Care, Lexington; Department of Epidemiology (MI), University of Kentucky, Lexington; and Lexington VA Health Care System (Troy Bowling Campus) (MI), US Department of Veterans Affairs, KY
| | - Hanwen Yuan
- Department of Neurology (KRN, KD, WW, MI), University of Kentucky, Lexington; Department of Neurology (WW), Uniformed Services University, Bethesda, MD; Performance Analytics Center of Excellence (HY), University of Kentucky Health Care, Lexington; Department of Epidemiology (MI), University of Kentucky, Lexington; and Lexington VA Health Care System (Troy Bowling Campus) (MI), US Department of Veterans Affairs, KY
| | - Mam Ibraheem
- Department of Neurology (KRN, KD, WW, MI), University of Kentucky, Lexington; Department of Neurology (WW), Uniformed Services University, Bethesda, MD; Performance Analytics Center of Excellence (HY), University of Kentucky Health Care, Lexington; Department of Epidemiology (MI), University of Kentucky, Lexington; and Lexington VA Health Care System (Troy Bowling Campus) (MI), US Department of Veterans Affairs, KY
| |
Collapse
|
8
|
Lisabeth LD, Brown DL, Zahuranec DB, Kim S, Lim J, Kerber KA, Meurer WJ, Case E, Smith MA, Campbell MS, Morgenstern LB. Temporal Trends in Ischemic Stroke Rates by Ethnicity, Sex, and Age (2000-2017): The Brain Attack Surveillance in Corpus Christi Project. Neurology 2021; 97:e2164-e2172. [PMID: 34584014 PMCID: PMC8641969 DOI: 10.1212/wnl.0000000000012877] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2021] [Accepted: 09/21/2021] [Indexed: 01/18/2023] Open
Abstract
OBJECTIVE To compare 18-year (2000-2017) temporal trends in ischemic stroke rates by ethnicity, sex, and age. METHODS Data are from a population-based stroke surveillance study conducted in Nueces County, Texas, a geographically isolated, biethnic, urban community. Active (screening hospital admission logs, hospital wards, intensive care units) and passive (screening inpatient/emergency department discharge diagnosis codes) surveillance were used to identify cases aged ≥45 (n = 4,875) validated by stroke physicians using a consistent stroke definition over time. Ischemic stroke rates were derived from Poisson regression using annual population counts from the US Census to estimate the at-risk population. RESULTS In those aged 45-59 years, rates increased in non-Hispanic Whites (104.3% relative increase; p < 0.001) but decreased in Mexican Americans (-21.9%; p = 0.03) such that rates were significantly higher in non-Hispanic Whites in 2016-2017 (p for ethnicity-time interaction < 0.001). In those age 60-74, rates declined in both groups but more so in Mexican Americans (non-Hispanic Whites -18.2%, p = 0.05; Mexican Americans -40.1%, p = 0.002), resulting in similar rates for the 2 groups in 2016-2017 (p for ethnicity-time interaction = 0.06). In those aged ≥75, trends did not vary by ethnicity, with declines noted in both groups (non-Hispanic Whites -33.7%, p = 0.002; Mexican Americans -26.9%, p = 0.02). Decreases in rates were observed in men (age 60-74, -25.7%, p = 0.009; age ≥75, -39.2%, p = 0.002) and women (age 60-74, -34.3%, p = 0.007; age ≥75, -24.0%, p = 0.02) in the 2 older age groups, while rates did not change in either sex in those age 45-59. CONCLUSION Previously documented ethnic stroke incidence disparities have ended as a result of declining rates in Mexican Americans and increasing rates in non-Hispanic Whites, most notably in midlife.
Collapse
Affiliation(s)
- Lynda D Lisabeth
- From the Departments of Epidemiology (L.D.L., E.C., M.A.S, L.B.M.) and Biostatistics (S.K., J.L.), University of Michigan School of Public Health; Stroke Program (L.D.L., D.L.B., D.B.Z., K.A.K., W.J.M., M.A.S, L.B.M.) and Department of Emergency Medicine (W.J.M., L.B.M.), University of Michigan Medical School, Ann Arbor; and CHRISTUS Spohn Hospitals (M.S.C.), CHRISTUS Health System, Corpus Christi, TX.
| | - Devin L Brown
- From the Departments of Epidemiology (L.D.L., E.C., M.A.S, L.B.M.) and Biostatistics (S.K., J.L.), University of Michigan School of Public Health; Stroke Program (L.D.L., D.L.B., D.B.Z., K.A.K., W.J.M., M.A.S, L.B.M.) and Department of Emergency Medicine (W.J.M., L.B.M.), University of Michigan Medical School, Ann Arbor; and CHRISTUS Spohn Hospitals (M.S.C.), CHRISTUS Health System, Corpus Christi, TX
| | - Darin B Zahuranec
- From the Departments of Epidemiology (L.D.L., E.C., M.A.S, L.B.M.) and Biostatistics (S.K., J.L.), University of Michigan School of Public Health; Stroke Program (L.D.L., D.L.B., D.B.Z., K.A.K., W.J.M., M.A.S, L.B.M.) and Department of Emergency Medicine (W.J.M., L.B.M.), University of Michigan Medical School, Ann Arbor; and CHRISTUS Spohn Hospitals (M.S.C.), CHRISTUS Health System, Corpus Christi, TX
| | - Sehee Kim
- From the Departments of Epidemiology (L.D.L., E.C., M.A.S, L.B.M.) and Biostatistics (S.K., J.L.), University of Michigan School of Public Health; Stroke Program (L.D.L., D.L.B., D.B.Z., K.A.K., W.J.M., M.A.S, L.B.M.) and Department of Emergency Medicine (W.J.M., L.B.M.), University of Michigan Medical School, Ann Arbor; and CHRISTUS Spohn Hospitals (M.S.C.), CHRISTUS Health System, Corpus Christi, TX
| | - Jaewon Lim
- From the Departments of Epidemiology (L.D.L., E.C., M.A.S, L.B.M.) and Biostatistics (S.K., J.L.), University of Michigan School of Public Health; Stroke Program (L.D.L., D.L.B., D.B.Z., K.A.K., W.J.M., M.A.S, L.B.M.) and Department of Emergency Medicine (W.J.M., L.B.M.), University of Michigan Medical School, Ann Arbor; and CHRISTUS Spohn Hospitals (M.S.C.), CHRISTUS Health System, Corpus Christi, TX
| | - Kevin A Kerber
- From the Departments of Epidemiology (L.D.L., E.C., M.A.S, L.B.M.) and Biostatistics (S.K., J.L.), University of Michigan School of Public Health; Stroke Program (L.D.L., D.L.B., D.B.Z., K.A.K., W.J.M., M.A.S, L.B.M.) and Department of Emergency Medicine (W.J.M., L.B.M.), University of Michigan Medical School, Ann Arbor; and CHRISTUS Spohn Hospitals (M.S.C.), CHRISTUS Health System, Corpus Christi, TX
| | - William J Meurer
- From the Departments of Epidemiology (L.D.L., E.C., M.A.S, L.B.M.) and Biostatistics (S.K., J.L.), University of Michigan School of Public Health; Stroke Program (L.D.L., D.L.B., D.B.Z., K.A.K., W.J.M., M.A.S, L.B.M.) and Department of Emergency Medicine (W.J.M., L.B.M.), University of Michigan Medical School, Ann Arbor; and CHRISTUS Spohn Hospitals (M.S.C.), CHRISTUS Health System, Corpus Christi, TX
| | - Erin Case
- From the Departments of Epidemiology (L.D.L., E.C., M.A.S, L.B.M.) and Biostatistics (S.K., J.L.), University of Michigan School of Public Health; Stroke Program (L.D.L., D.L.B., D.B.Z., K.A.K., W.J.M., M.A.S, L.B.M.) and Department of Emergency Medicine (W.J.M., L.B.M.), University of Michigan Medical School, Ann Arbor; and CHRISTUS Spohn Hospitals (M.S.C.), CHRISTUS Health System, Corpus Christi, TX
| | - Melinda A Smith
- From the Departments of Epidemiology (L.D.L., E.C., M.A.S, L.B.M.) and Biostatistics (S.K., J.L.), University of Michigan School of Public Health; Stroke Program (L.D.L., D.L.B., D.B.Z., K.A.K., W.J.M., M.A.S, L.B.M.) and Department of Emergency Medicine (W.J.M., L.B.M.), University of Michigan Medical School, Ann Arbor; and CHRISTUS Spohn Hospitals (M.S.C.), CHRISTUS Health System, Corpus Christi, TX
| | - Morgan S Campbell
- From the Departments of Epidemiology (L.D.L., E.C., M.A.S, L.B.M.) and Biostatistics (S.K., J.L.), University of Michigan School of Public Health; Stroke Program (L.D.L., D.L.B., D.B.Z., K.A.K., W.J.M., M.A.S, L.B.M.) and Department of Emergency Medicine (W.J.M., L.B.M.), University of Michigan Medical School, Ann Arbor; and CHRISTUS Spohn Hospitals (M.S.C.), CHRISTUS Health System, Corpus Christi, TX
| | - Lewis B Morgenstern
- From the Departments of Epidemiology (L.D.L., E.C., M.A.S, L.B.M.) and Biostatistics (S.K., J.L.), University of Michigan School of Public Health; Stroke Program (L.D.L., D.L.B., D.B.Z., K.A.K., W.J.M., M.A.S, L.B.M.) and Department of Emergency Medicine (W.J.M., L.B.M.), University of Michigan Medical School, Ann Arbor; and CHRISTUS Spohn Hospitals (M.S.C.), CHRISTUS Health System, Corpus Christi, TX
| |
Collapse
|
9
|
Byon HD, Ahn S, Yan G, Crandall M, LeBaron V. Association of a Substance Use Disorder with Infectious Diseases among Adult Home Healthcare Patients with a Venous Access Device. Home Healthc Now 2021; 39:320-326. [PMID: 34738967 DOI: 10.1097/nhh.0000000000001009] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Substance use disorders (SUDs) and high incidence of infectious diseases are both critical public health issues. Among patients who use a venous access device (VAD) in home care settings, SUDs may play a role in increasing their risk of having a concurrent infectious disease. This study examined the association of SUD with infectious diseases among adult home healthcare patients with a VAD. We identified adult patients with an existing VAD who were admitted to a home healthcare agency August 1, 2017-July 31, 2018 from the electronic health records of a large Medicare-certified agency. Four serious infectious diseases (endocarditis, epidural abscess, septic arthritis, and osteomyelitis) and SUD related to injectable drugs were identified using relevant ICD-10 codes. Multiple logistic regression was performed to examine the association. Of 416 patients with a VAD, 12% (n = 50) had at least one diagnosis of a serious infectious disease. The percentage of patients who had a serious infectious disease was 40% among those with SUDs, compared with only 11% among those without SUDs. After adjusting for age and sex, the odds of having a serious infectious disease was 3.52 times greater for those with SUDs compared with those without (odds ratio [95% confidence interval], 4.52 [1.48-13.79], n = .008). Our findings suggest that home healthcare patients with a VAD and a documented SUD diagnosis may have an increased risk of having a concurrent serious infectious disease. Therefore, patients with an SUD and a VAD would need more attention from home healthcare providers to prevent a serious infectious disease. Further research is suggested on modalities of care for individuals with an SUD and VAD to reduce the incidence of infectious diseases so that care can be delivered safely and efficiently in a home healthcare setting.
Collapse
|
10
|
Chow SL, Sasson C, Benjamin IJ, Califf RM, Compton WM, Oliva EM, Robson C, Sanchez EJ. Opioid Use and Its Relationship to Cardiovascular Disease and Brain Health: A Presidential Advisory From the American Heart Association. Circulation 2021; 144:e218-e232. [PMID: 34407637 DOI: 10.1161/cir.0000000000001007] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The misuse of opioids continues to be epidemic, resulting in dependency and a recent upsurge in drug overdoses that have contributed to a significant decrease in life expectancy in the United States. Moreover, recent data suggest that commonly used opioids for the management of pain may produce undesirable pharmacological actions and interfere with critical medications commonly used in cardiovascular disease and stroke; however, the impact on outcomes remains controversial. The American Heart Association developed an advisory statement for health care professionals and researchers in the setting of cardiovascular and brain health to synthesize the current literature, to provide approaches for identifying patients with opioid use disorder, and to address pain management and overdose. A literature and internet search spanning from January 1, 2012, to February 15, 2021, and limited to epidemiology studies, reviews, consensus statements, and guidelines in human subjects was conducted. Suggestions and considerations listed in this document are based primarily on published evidence from this review whenever possible, as well as expert opinion. Several federal and institutional consensus documents and clinical resources are currently available to both patients and clinicians; however, none have specifically addressed cardiovascular disease and brain health. Although strategic tools and therapeutic approaches for recognition of opioid use disorder and safe opioid use are available for health care professionals who manage patients with cardiovascular disease and stroke, high-quality evidence does not currently exist. Therefore, there is an urgent need for more research to identify the most effective approaches to improve care for these patients.
Collapse
|
11
|
Kitchen SA, McCormack D, Werb D, Caudarella A, Martins D, Matheson FI, Gomes T. Trends and outcomes of serious complications associated with non-fatal opioid overdoses in Ontario, Canada. Drug Alcohol Depend 2021; 225:108830. [PMID: 34182376 DOI: 10.1016/j.drugalcdep.2021.108830] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/02/2021] [Revised: 04/29/2021] [Accepted: 05/10/2021] [Indexed: 01/04/2023]
Abstract
BACKGROUND Non-fatal opioid overdoses can lead to serious complications and consequently, long-term health effects. We sought to characterize trends of hospitalizations for serious complications associated with opioid overdoses in Ontario, Canada and report health services utilization and mortality in the year following hospital discharge. METHODS We conducted a cross-sectional study in Ontario among individuals who experienced a hospitalization for a serious complication (required intubation, rhabdomyolysis, or a brain injury) associated with an opioid overdose between 2010 and 2019. We examined inpatient characteristics at the time of hospital admission, and health services utilization and mortality rates in the year following hospital discharge. RESULTS The rate of hospitalizations for serious complications associated with opioid overdoses increased by 66.7 % from 1.8 per 100,000 population in 2010 to 3.0 per 100,000 population in 2019 in Ontario. Individuals that were discharged alive from hospital experienced high health services utilization in the following year; 71.2 % (N = 953 of 1,338) visited the emergency department (ED), 34.2 % (N = 458) were admitted to hospital, and 16.4 % (N = 219) were treated in hospital for an opioid overdose. However only a quarter of individuals (N = 332; 24.8 %) initiated on opioid agonist therapy within 90 days. Additionally, 8.0 % (N = 127) of hospitalizations resulted in death within 1 year. CONCLUSIONS This study highlights increasing rates of serious complications associated with opioid overdoses, with a high demand of health services and a high mortality rate in the following year. These findings highlight an ongoing need for support and harm reduction services to allow for early intervention and follow-up care.
Collapse
Affiliation(s)
- Sophie A Kitchen
- Unity Health Toronto and Li Ka Shing Knowledge Institute of St. Michael's Hospital, 30 Bond St, Toronto, Ontario, M5B 1W8, Canada; Ontario Drug Policy Research Network, 30 Bond St, Toronto, Ontario, M5B 1W8, Canada; Institute for Clinical Evaluative Sciences, 2075 Bayview Ave, Toronto, Ontario, M4N 3M5, Canada
| | - Daniel McCormack
- Ontario Drug Policy Research Network, 30 Bond St, Toronto, Ontario, M5B 1W8, Canada; Institute for Clinical Evaluative Sciences, 2075 Bayview Ave, Toronto, Ontario, M4N 3M5, Canada
| | - Dan Werb
- Unity Health Toronto and Li Ka Shing Knowledge Institute of St. Michael's Hospital, 30 Bond St, Toronto, Ontario, M5B 1W8, Canada; Division of Infectious Diseases and Global Public Health, UC San Diego, 9500 Gilman Dr, San Diego, CA, 92161, USA; Centre on Drug Policy Evaluation, UC San Diego, 9500 Gilman Dr, San Diego, CA, 92161, USA
| | - Alexander Caudarella
- Mental Health and Addictions Service, St. Michael's Hospital, 30 Bond St, Toronto, Ontario, M5B 1W8, Canada
| | - Diana Martins
- Unity Health Toronto and Li Ka Shing Knowledge Institute of St. Michael's Hospital, 30 Bond St, Toronto, Ontario, M5B 1W8, Canada; Ontario Drug Policy Research Network, 30 Bond St, Toronto, Ontario, M5B 1W8, Canada
| | - Flora I Matheson
- Unity Health Toronto and Li Ka Shing Knowledge Institute of St. Michael's Hospital, 30 Bond St, Toronto, Ontario, M5B 1W8, Canada; MAP Centre for Urban Health Solutions, St. Michael's Hospital, 30 Bond St, Toronto, Ontario, M5B 1W8, Canada
| | - Tara Gomes
- Unity Health Toronto and Li Ka Shing Knowledge Institute of St. Michael's Hospital, 30 Bond St, Toronto, Ontario, M5B 1W8, Canada; Ontario Drug Policy Research Network, 30 Bond St, Toronto, Ontario, M5B 1W8, Canada; Institute for Clinical Evaluative Sciences, 2075 Bayview Ave, Toronto, Ontario, M4N 3M5, Canada.
| |
Collapse
|
12
|
Cardiovascular Complications of Opioid Use: JACC State-of-the-Art Review. J Am Coll Cardiol 2021; 77:205-223. [PMID: 33446314 DOI: 10.1016/j.jacc.2020.11.002] [Citation(s) in RCA: 49] [Impact Index Per Article: 16.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/04/2020] [Revised: 10/30/2020] [Accepted: 11/02/2020] [Indexed: 12/29/2022]
Abstract
Opioids are the most potent of all analgesics. Although traditionally used solely for acute self-limited conditions and palliation of severe cancer-associated pain, a movement to promote subjective pain (scale, 0 to 10) to the status of a "fifth vital sign" bolstered widespread prescribing for chronic, noncancer pain. This, coupled with rising misuse, initiated a surge in unintentional deaths, increased drug-associated acute coronary syndrome, and endocarditis. In response, the American College of Cardiology issued a call to action for cardiovascular care teams. Opioid toxicity is primarily mediated via potent μ-receptor agonism resulting in ventilatory depression. However, both overdose and opioid withdrawal can trigger major adverse cardiovascular events resulting from hemodynamic, vascular, and proarrhythmic/electrophysiological consequences. Although natural opioid analogues are devoid of repolarization effects, synthetic agents may be proarrhythmic. This perspective explores cardiovascular consequences of opioids, the contributions of off-target electrophysiologic properties to mortality, and provides practical safety recommendations.
Collapse
|
13
|
Singleton JH, Abner EL, Akpunonu PD, Kucharska‐Newton AM. Association of Nonacute Opioid Use and Cardiovascular Diseases: A Scoping Review of the Literature. J Am Heart Assoc 2021; 10:e021260. [PMID: 34212763 PMCID: PMC8403306 DOI: 10.1161/jaha.121.021260] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
BACKGROUND In this scoping review, we identified and reviewed 23 original articles from the PubMed database that investigated the relationship between nonacute opioid use (NOU) and cardiovascular outcomes. METHODS AND RESULTS We defined NOU to include both long-term opioid therapy and opioid use disorder. We summarized the association between NOU and 5 classes of cardiovascular disease, including infective endocarditis, coronary heart disease (including myocardial infarction), congestive heart failure, cardiac arrythmia (including cardiac arrest), and stroke. The most commonly studied outcomes were coronary heart disease and infective endocarditis. There was generally consistent evidence of a positive association between community prevalence of injection drug use (with opioids being the most commonly injected type of drug) and community prevalence of infective endocarditis, and between (primarily medically indicated) NOU and myocardial infarction. There was less consensus about the relationship between NOU and congestive heart failure, cardiac arrhythmia, and stroke. CONCLUSIONS There is a dearth of high-quality evidence on the relationship between NOU and cardiovascular disease. Innovative approaches to the assessment of opioid exposure over extended periods of time will be required to address this need.
Collapse
Affiliation(s)
- Jade H. Singleton
- Department of EpidemiologyCollege of Public HealthUniversity of KentuckyLexingtonKY
| | - Erin L. Abner
- Department of EpidemiologyCollege of Public HealthUniversity of KentuckyLexingtonKY
| | - Peter D. Akpunonu
- Emergency Medicine & Medical ToxicologyUniversity of Kentucky HospitalLexingtonKY
| | | |
Collapse
|
14
|
Kleindorfer DO, Towfighi A, Chaturvedi S, Cockroft KM, Gutierrez J, Lombardi-Hill D, Kamel H, Kernan WN, Kittner SJ, Leira EC, Lennon O, Meschia JF, Nguyen TN, Pollak PM, Santangeli P, Sharrief AZ, Smith SC, Turan TN, Williams LS. 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. Stroke 2021; 52:e364-e467. [PMID: 34024117 DOI: 10.1161/str.0000000000000375] [Citation(s) in RCA: 1032] [Impact Index Per Article: 344.0] [Reference Citation Analysis] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
|
15
|
Dezfulian C, Orkin AM, Maron BA, Elmer J, Girotra S, Gladwin MT, Merchant RM, Panchal AR, Perman SM, Starks MA, van Diepen S, Lavonas EJ. Opioid-Associated Out-of-Hospital Cardiac Arrest: Distinctive Clinical Features and Implications for Health Care and Public Responses: A Scientific Statement From the American Heart Association. Circulation 2021; 143:e836-e870. [PMID: 33682423 DOI: 10.1161/cir.0000000000000958] [Citation(s) in RCA: 50] [Impact Index Per Article: 16.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
Opioid overdose is the leading cause of death for Americans 25 to 64 years of age, and opioid use disorder affects >2 million Americans. The epidemiology of opioid-associated out-of-hospital cardiac arrest in the United States is changing rapidly, with exponential increases in death resulting from synthetic opioids and linear increases in heroin deaths more than offsetting modest reductions in deaths from prescription opioids. The pathophysiology of polysubstance toxidromes involving opioids, asphyxial death, and prolonged hypoxemia leading to global ischemia (cardiac arrest) differs from that of sudden cardiac arrest. People who use opioids may also develop bacteremia, central nervous system vasculitis and leukoencephalopathy, torsades de pointes, pulmonary vasculopathy, and pulmonary edema. Emergency management of opioid poisoning requires recognition by the lay public or emergency dispatchers, prompt emergency response, and effective ventilation coupled to compressions in the setting of opioid-associated out-of-hospital cardiac arrest. Effective ventilation is challenging to teach, whereas naloxone, an opioid antagonist, can be administered by emergency medical personnel, trained laypeople, and the general public with dispatcher instruction to prevent cardiac arrest. Opioid education and naloxone distributions programs have been developed to teach people who are likely to encounter a person with opioid poisoning how to administer naloxone, deliver high-quality compressions, and perform rescue breathing. Current American Heart Association recommendations call for laypeople and others who cannot reliably establish the presence of a pulse to initiate cardiopulmonary resuscitation in any individual who is unconscious and not breathing normally; if opioid overdose is suspected, naloxone should also be administered. Secondary prevention, including counseling, opioid overdose education with take-home naloxone, and medication for opioid use disorder, is important to prevent recurrent opioid overdose.
Collapse
|
16
|
Zuflacht JP, Fehnel CR. Delayed Cerebral Abscess Formation After Posterior Cerebral Artery Stroke in a Patient With Opioid Use Disorder. Stroke 2021; 52:e100-e103. [PMID: 33567875 DOI: 10.1161/strokeaha.120.031081] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- Jonah P Zuflacht
- Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA (J.P.Z., C.R.F.)
| | - Corey R Fehnel
- Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA (J.P.Z., C.R.F.).,Hinda and Arthur Marcus Institute for Aging Research, Boston, MA (C.R.F.)
| |
Collapse
|
17
|
Chum A, Wang R, Nisenbaum R, O'Campo P, Stergiopoulos V, Hwang S. Effect of a Housing Intervention on Selected Cardiovascular Risk Factors Among Homeless Adults With Mental Illness: 24-Month Follow-Up of a Randomized Controlled Trial. J Am Heart Assoc 2020; 9:e016896. [PMID: 32975159 PMCID: PMC7792403 DOI: 10.1161/jaha.119.016896] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Background Cardiovascular disease is a leading cause of mortality among people experiencing homelessness. This study investigated whether housing intervention affects cardiovascular disease risk factors among homeless adults with mental illnesses over a 24-month period. Methods and Results We conducted a randomized controlled trial of a Housing First intervention that provided community-based scattered-site housing and support services. Five hundred seventy-five participants were randomized to the intervention (n=301) or treatment as usual (TAU) (n=274). Analyses were performed according to the intention-to-treat principle using generalized estimating equations. There were no differences in change over 24 months between the 2 groups for blood pressure, tobacco, and cocaine/crack use. However, the intervention had an impact on reducing the number of days of alcohol intoxication by 1.58 days compared with TAU (95% CI, -2.88 to -0.27, P=0.0018). Over the 24-month period, both the intervention and TAU groups had significant reductions in tobacco and cocaine use. Conclusions The intervention, compared with TAU, did not result in greater improvements in many of the selected cardiovascular risk factors. Since the study took place in a service-rich city with a range of pre-existing supportive services and universal health insurance, the high level of usual services available to the TAU group may have contributed to reductions in their cardiovascular disease risk factors. Further research is needed to develop interventions to reduce risk factors of cardiovascular disease among people experiencing homelessness and mental illness beyond existing treatments. REGISTRATION www.isrctn.comURL: www.isrctn.com. Unique Identifier: ISRCTN42520374.
Collapse
Affiliation(s)
- Antony Chum
- Brock University St. Catharines ON Canada.,Unity Health Toronto Toronto ON Canada
| | - Ri Wang
- Unity Health Toronto Toronto ON Canada
| | | | | | - Vicky Stergiopoulos
- Unity Health Toronto Toronto ON Canada.,Centre for Addiction and Mental Health Toronto ON Canada
| | | |
Collapse
|
18
|
Branyan TE, Sohrabji F. Sex differences in stroke co-morbidities. Exp Neurol 2020; 332:113384. [PMID: 32585156 PMCID: PMC7418167 DOI: 10.1016/j.expneurol.2020.113384] [Citation(s) in RCA: 33] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2020] [Revised: 06/06/2020] [Accepted: 06/15/2020] [Indexed: 12/12/2022]
Abstract
Males and females possess distinct biological differences that manifest in diverse risk profiles for acute and chronic diseases. A well-documented example of this is ischemic stroke. It has been demonstrated that older females have greater prevalence of, and worse outcome after, ischemic stroke than do males and younger females. Loss of estrogen after menopause is heavily implicated as a contributing factor for this phenomenon; however, there is mounting evidence to suggest that certain risk factors tend to occur more often in older females, such as hypertension and atrial fibrillation, while others more adversely affect females than they do males, such as diabetes and smoking. Sex-specific risk factors, such as oral contraceptive use and menopause, could also contribute to the discrepancy in stroke prevalence and outcome. Additionally, there is evidence to suggest that females tend to present with more nontraditional symptoms of acute stroke than do males, making it more difficult for clinicians to correctly identify the occurrence of a stroke, which may delay the administration of thrombolytic intervention. Finally, certain sociodemographic factors, such as the fact that females were more likely to live alone prior to stroke, may contribute to poorer recovery in females. This review will explore the various co-morbidities and sociodemographic factors that contribute to the greater prevalence of and poorer outcome after stroke in older females and will highlight the critical need for considering sex as a predisposing biological variable in stroke studies.
Collapse
Affiliation(s)
- Taylor E Branyan
- Women's Health in Neuroscience Program, Department of Neuroscience and Experimental Therapeutics, Texas A&M HSC College of Medicine, Bryan, TX 77807, USA; Texas A&M Institute for Neuroscience, College Station, TX 77840, USA
| | - Farida Sohrabji
- Women's Health in Neuroscience Program, Department of Neuroscience and Experimental Therapeutics, Texas A&M HSC College of Medicine, Bryan, TX 77807, USA; Texas A&M Institute for Neuroscience, College Station, TX 77840, USA.
| |
Collapse
|
19
|
Kim JH, Fine DR, Li L, Kimmel SD, Ngo LH, Suzuki J, Price CN, Ronan MV, Herzig SJ. Disparities in United States hospitalizations for serious infections in patients with and without opioid use disorder: A nationwide observational study. PLoS Med 2020; 17:e1003247. [PMID: 32764761 PMCID: PMC7413412 DOI: 10.1371/journal.pmed.1003247] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/14/2020] [Accepted: 07/08/2020] [Indexed: 01/18/2023] Open
Abstract
BACKGROUND Patients with opioid use disorder (OUD) who are hospitalized for serious infections requiring prolonged intravenous antibiotics may face barriers to discharge, which could prolong hospital length of stay (LOS) and increase financial burden. We investigated differences in LOS, discharge disposition, and charges between hospitalizations for serious infections in patients with and without OUD. METHODS AND FINDINGS We utilized the 2016 National Inpatient Sample-a nationally representative database of all discharges from US acute care hospitals. The population of interest was all hospitalizations for infective endocarditis, epidural abscess, septic arthritis, or osteomyelitis. The exposure was OUD, and the primary outcome was LOS until discharge, assessed by using a competing risks analysis to estimate adjusted hazard ratios (aHRs). Adjusted odds ratio (aOR) of discharge disposition and adjusted differences in hospital charges were also reported. Of 95,470 estimated hospitalizations for serious infections (infective endocarditis, epidural abscess, septic arthritis, and osteomyelitis), the mean age was 49 years and 35% were female. 46% had Medicare (government-based insurance coverage for people age 65+ years), and 70% were non-Hispanic white. After adjustment for potential confounders, OUD was associated with a lower probability of discharge at any given LOS (aHR 0.61; 95% CI 0.59-0.63; p < 0.001). OUD was also associated with lower odds of discharge to home (aOR 0.38; 95% CI 0.33-0.43; p < 0.001) and higher odds of discharge to a post-acute care facility (aOR 1.85; 95% CI 1.57-2.17; p < 0.001) or patient-directed discharge (also referred to as "discharge against medical advice") (aOR 3.47; 95% CI 2.80-4.29; p < 0.001). There was no significant difference in average total hospital charges, though daily hospital charges were significantly lower for patients with OUD. Limitations include the potential for unmeasured confounders and the use of billing codes to identify cohorts. CONCLUSIONS Our findings suggest that among hospitalizations for some serious infections, those involving patients with OUD were associated with longer LOS, higher odds of discharge to post-acute care facilities or patient-directed discharge, and similar total hospital charges, despite lower daily charges. These findings highlight opportunities to improve care for patients with OUD hospitalized with serious infections, and to reduce the growing associated costs.
Collapse
Affiliation(s)
- June-Ho Kim
- Division of General Internal Medicine and Primary Care, Department of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts, United States of America
- Harvard Medical School, Boston, Massachusetts, United States of America
- Ariadne Labs, Brigham and Women’s Hospital and Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America
| | - Danielle R. Fine
- Harvard Medical School, Boston, Massachusetts, United States of America
- Division of General Internal Medicine, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, United States of America
| | - Lily Li
- Harvard Medical School, Boston, Massachusetts, United States of America
- Division of Rheumatology, Immunology and Allergy, Department of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts, United States of America
| | - Simeon D. Kimmel
- Section of Infectious Diseases, Department of Medicine, Boston Medical Center, Boston, Massachusetts, United States of America
- Section of General Internal Medicine, Department of Medicine, Boston Medical Center, Boston, Massachusetts, United States of America
| | - Long H. Ngo
- Harvard Medical School, Boston, Massachusetts, United States of America
- Division of General Medicine, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America
| | - Joji Suzuki
- Harvard Medical School, Boston, Massachusetts, United States of America
- Department of Psychiatry, Brigham and Women’s Hospital, Boston, Massachusetts, United States of America
| | - Christin N. Price
- Harvard Medical School, Boston, Massachusetts, United States of America
- Brigham and Women’s Physicians Organization, Brigham and Women’s Hospital, Boston, Massachusetts, United States of America
| | - Matthew V. Ronan
- Department of Medicine, West Roxbury VA Medical Center, Veterans Affairs Boston Healthcare System, Boston, Massachusetts, United States of America
| | - Shoshana J. Herzig
- Harvard Medical School, Boston, Massachusetts, United States of America
- Division of General Medicine, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America
| |
Collapse
|
20
|
Affiliation(s)
- Mary G. George
- Division for Heart Disease and Stroke Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia
| |
Collapse
|
21
|
Aparicio HJ, Himali JJ, Satizabal CL, Pase MP, Romero JR, Kase CS, Beiser AS, Seshadri S. Temporal Trends in Ischemic Stroke Incidence in Younger Adults in the Framingham Study. Stroke 2019; 50:1558-1560. [PMID: 31084341 PMCID: PMC6538454 DOI: 10.1161/strokeaha.119.025171] [Citation(s) in RCA: 31] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
Background and Purpose- Stroke at midlife has a disproportionately large impact on disability-adjusted life-years lost. Ischemic stroke incidence may be increasing at this age. We investigated long-term trends in ischemic stroke incidence and changes in stroke risk factors in a community sample stratified by stroke onset at middle and older age. Methods- In the Framingham Study, surveillance for incident stroke is ongoing since 1948. We examined age-adjusted and sex-adjusted 10-year incidence of ischemic stroke using Cox models in persons aged 35 to 54 and ≥55 years at start of follow-up. Tests for linear trend were performed over 4 epochs, controlling for the distance in time between intervals. Further, we calculated the mean 10-year risk of stroke at each epoch and for both age groups, based on vascular risk factors from the Framingham Stroke Risk Profile. Results- There were 153, 197, 176, and 165 incident ischemic strokes within each epoch beginning in 1962 (n=3966), 1971 (n=5779), 1987 (n=5133), and 1998 (n=6964). Most ischemic strokes at midlife (n=71) were because of atherosclerotic brain infarction (n=50) or cardioembolism (n=19). Using the risk in the 1962 epoch as the reference, the risk of ischemic stroke at midlife did not significantly decline (hazard ratio, 0.87; 95% CI, 0.74-1.02; P trend =0.09). Incidence of ischemic stroke declined in the older group (hazard ratio, 0.82; 95% CI, 0.77-0.88; P trend <0.001). Between epochs 1 and 4, the average 10-year risk of stroke, as estimated by the Framingham Stroke Risk Profile, declined by 0.7% at midlife and 1.1% at older age. Conclusions- Long-term rates of ischemic stroke declined in our community sample; the decline was greater in older as compared with younger adults. Early prevention, focused on modification of cardiovascular risk factors, is important to see sustained declines in stroke incidence and mortality at midlife.
Collapse
Affiliation(s)
| | | | - Claudia L. Satizabal
- Boston University School of Medicine, MA, USA
- University of Texas Health Sciences Center, TX, USA
| | - Matthew P. Pase
- The Florey Institute for Neuroscience and Mental Health,
Melbourne, Australia
- The University of Melbourne, Australia
- Swinburne University of Technology, Hawthorne,
Australia
| | | | - Carlos S. Kase
- Boston University School of Medicine, MA, USA
- Emory University, Atlanta, GA, USA
| | | | - Sudha Seshadri
- Boston University School of Medicine, MA, USA
- University of Texas Health Sciences Center, TX, USA
| |
Collapse
|
22
|
Thakkar S, Doshi R. Letter by Thakkar and Doshi Regarding Article, "National Trends in Hospitalizations for Stroke Associated With Infective Endocarditis and Opioid Use Between 1993 and 2015". Stroke 2019; 50:e162. [PMID: 31018779 DOI: 10.1161/strokeaha.119.025317] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
| | - Rajkumar Doshi
- Department of Internal Medicine, University of Nevada Reno School of Medicine, Reno, NV
| |
Collapse
|
23
|
Salehi Omran S, Kamel H. Response by Salehi Omran and Kamel to Letter Regarding Article, "National Trends in Hospitalizations for Stroke Associated With Infective Endocarditis and Opioid Use Between 1993 and 2015". Stroke 2019; 50:e163. [PMID: 31018780 DOI: 10.1161/strokeaha.119.025507] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- Setareh Salehi Omran
- Department of Neurology, Vagelos College of Physicians and Surgeons, Columbia University Medical Center, New York, NY
| | - Hooman Kamel
- Clinical and Translational Neuroscience Unit, Feil Family Brain and Mind Research Institute and Department of Neurology, Weill Cornell Medicine, New York, NY
| |
Collapse
|